Cost–effectiveness analysis of genetic screening for the Taq1B polymorphism in the secondary prevention of coronary heart disease

References

• Mathers C, Vos T, Stevenson C. The Burden of Disease and Injury in Australia. Australian Institute of Health and Welfare, Canberra, Australia, cat. no. PHE 17 (1999).
   Google Scholar
• Australian Institute of Health and Welfare. Heart, stroke and vascular diseases – Australian facts 2004. In: Cardiovascular Disease Series No. 22. Australian Institute of Health and Welfare, Canberra (2004).
   Google Scholar
• Australian Institute of Health and Welfare. Health System Expenditure on Disease and Injury in Australia, 2000–01. In: Health and Welfare Expenditure Series no. 19. Australian Institute of Health and Welfare, Canberra, Australia (2004).
   Google Scholar
• Australian Institute of Health and Welfare. Secondary Prevention and Rehabilitation after Coronary Events or Stroke. Australian Institute of Health and Welfare, Canberra, Australia (2003).
   Google Scholar
• Brousseau ME, O’Connor JJ, Ordovas JM et al. Cholesteryl ester transfer protein Taq1 B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency. Arterioscler. Thromb. Vasc. Biol.22(7), 1148–1154 (2002).
   Google Scholar
• Dornbrook-Lavender KA, Pieper JA. Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy. Cardiovasc. Drugs Ther.17, 75–82 (2003).
   Google Scholar
• Mukherjee D, Topol EJ. Pharmacogenomics in cardiovascular disease. Curr. Probl. Cardiol.48(5), 317–347 (2003).
   Google Scholar
• Barter JP, Brewer HB, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein. Arterioscler. Thromb. Vasc. Biol.23(2), 160–167 (2003).
   Google Scholar
• Corella D, Saiz C, Guillen M et al. Association of TaqIB polymorphism in the cholesteryl ester transfer protein gene with plasma lipid levels in a healthy Spanish population. Atherosclerosis152(2), 367–376 (2000).
   PubMed Web of Science ®Google Scholar
• Jonsson B. Economics of drug treatment: for which patients is it cost-effective to lower cholesterol? Lancet358(9289), 1251–1256 (2001).
   Google Scholar
• Riviere M, Wang S, Leclerc C et al. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. Can. Med. Assoc. J.156(7), 991–997 (1997).
   Google Scholar
• Kmietowicz Z. UK review finds statins are cost effective in secondary prevention. Br. Med. J.319(7222), 1390 (1999).
   Google Scholar
• Szucs TD, Bertel O, Darioli R et al. Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarctor unstable angina pectoris. An analysis based on the LIPID Study. Schweiz. Rundsch. Med. Prax.89(18), 745–752 (2000).
   Google Scholar
• Carlquist JF, Muhlestein JB, Horne BD et al. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am. Heart J.146(6), 1007–1014 (2003).
   PubMed Web of Science ®Google Scholar
• Ordovas JM, Cupples LA, Corella D et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk. Arterioscler. Thromb. Vasc. Biol.20(5), 1323–1329 (2000).
   Google Scholar
• Australian Government Department of Health and Ageing. Medicare Benefits Schedule Book. Commonwealth Department of Health and Ageing, Canberra, Australia (2003).
   Google Scholar
• Australian Government Department of Health and Ageing. Schedule of Pharmaceutical Benefits Effective from 1 May 2004. Commonwealth Department of Health and Ageing (2004).
   Google Scholar
• Australian Government Department of Health and Ageing. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners: Operative from 1 April 2005. Australian Government Department of Health and Ageing, Canberra, Australia (2005).
   Google Scholar
• Australian Prescription Products Guide. Thomas J (Ed.). Australian Pharmaceutical Publishing Company, Victoria, Australia (2003).
   Google Scholar
• Dewey HM, Thrift AG, Mihalopoulos C et al. Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke32(10), 2409–2416 (2001).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, He J, Vuppututri S. Effects of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA282(24), 2340–2346 (1999).
   PubMed Web of Science ®Google Scholar
• Knuiman MW, Vu HT. Risk factors for stroke mortality in men and women: the Busselton Study. J. Cardiovasc. Risk,3(5), 447–452 (1996).
   Google Scholar
• Knuiman MW, Vu HT. Prediction of coronary heart disease mortality in Busselton, Western Australia: an evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores. J. Epidemiol. Community Health51(5), 515–519 (1997).
   Google Scholar
• Knuiman MW, Vu HT, Bartholomew HC. Multivariate risk estimation for coronary heart disease: the Busselton Health Study. Aust. NZ J. Public Health22(7), 747–753 (1998).
   Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation.107(19), 2409–2415 (2003).
   PubMed Web of Science ®Google Scholar
• Davidson MH, McGarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol.40(12), 2125–2134 (2002).
   PubMed Web of Science ®Google Scholar
• Feldman T, Koren M, Insull W Jr et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am. J. Cardiol.93(12), 1481–1486 (2004).
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Sapre A, Liu J et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin. Proc.79(5), 620–629 (2004).
   PubMed Web of Science ®Google Scholar
• Kerzner B, Corbelli J, Sharp S et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am. J. Cardiol.91(4), 418–424 (2003).
   PubMed Web of Science ®Google Scholar
• Melani L, Mills R, Hassman D et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur. Heart J.24(8), 717–728 (2003).
   PubMed Web of Science ®Google Scholar
• Sager PT, Melani L, Lipka L et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am. J. Cardiol.92(12), 1414–1418 (2003).
   PubMed Web of Science ®Google Scholar
• Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ. A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul. Health Metr.1(1), 4 (2003).
   PubMedGoogle Scholar
• Vos T, Begg S. Victorian Burden of Disease Study: Mortality. Public Health and Development Division, Department of Human Services, Melbourne (1999).
   Google Scholar
• @RISK [computer program]. Palisade Corporation, New York (2002).
   Google Scholar
• Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med. J. Aust.164(4), 208–211 (1996).
   PubMed Web of Science ®Google Scholar
• Simons LA, Simons J, McManus P, Dudley J. Discontinuation rates for use of statins are high. Br. Med. J.321(7268), 1084 (2000).
   Google Scholar
• Lokuge B, Faunce TA, Denniss R. A Backdoor to Higher Medicine Prices? Intellectual Property and the Australia-US Free Trade Agreement. The Australia Institute, Canberra (2003)
   Google Scholar
• Van Venrooij FV, Stolk RP, Banga JD et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care26(4), 1216–1331 (2003).
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JA, Jukema JW, Zwinderman AH et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N. Engl. J. Med.338(2), 86–92 (1998).
   PubMed Web of Science ®Google Scholar
• de Grooth GJ, Zerba KE, Huang SP et al. The cholesterol ester transfer protein (CETP) Taq1B polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome. J. Am. Coll. Cardiol.,43(5), 854–857 (2004).
   PubMed Web of Science ®Google Scholar
• Klerkx AH, de Grooth GJ, Zwinderman AH et al. Cholesteryl estertransfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur. J. Clin. Invest.34(7), 21–28 (2004).
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Sacks FM, Jukema JW et al. Cholesteryl ester transfer protein Taq1B variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation111(3), 278–287 (2005).
   PubMed Web of Science ®Google Scholar
• Klerkx AHEM, Tanck MWT, Kastelein JJP et al. Haplotype analysis of the CETP gene: not Taq1B, but the closely linked 629C-A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum. Mol. Genet.12(2), 111–123 (2003).
   PubMed Web of Science ®Google Scholar
• Maitland-van der Zee AH, Klungel OH, Stricker BHC et al. Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting β-hydroxy-β-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics14(1), 53–60 (2004).
   Google Scholar
• Thrift AG, Dewey HM, Macdonell RA et al. Incidence of the major stroke subtypes: initial findings from the North East Melbourne stroke incidence study (NEMESIS). Stroke32(8), 1732–1738 (2001).
   PubMed Web of Science ®Google Scholar
• Thrift AG, Dewey HM, Macdonell RA et al. Stroke incidence on the east coast of Australia: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke31(9), 2087–2092 (2000).
   PubMed Web of Science ®Google Scholar
• Bonita R, Broad JB, Beaglehole R. Changes in stroke incidence and case-fatality in Auckland, New Zealand, 1981–91. Lancet342(8885), 1470–1473 (1993).
   PubMed Web of Science ®Google Scholar